Schrödinger expands Bristol Myers Squibb partnership with AI co-scientist deal

Why Schrödinger CEO Ramy Farid changed how he's thinking about AI

In this edition of STAT's AI Prognosis newsletter: Why companies like Schrödinger and Centene are rethinking AI, Recursion's neuron map, and more health AI news.

Schrödinger expands Bristol Myers Squibb partnership with AI co-scientist deal

Schrödinger (SDGR) expands its Bristol Myers Squibb partnership to deploy Bunsen agentic AI, accelerating drug discovery with RetroSynth integration—read...

Schrödinger and BMS expand partnership to deploy AI for drug discovery

This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger’s computational platform for drug discovery projects. The new arrangement will extend The post Schrödinger and BMS expand partnership to deploy AI for drug discovery appeared first on Pharmaceutical Business review.